Advertisements

Зодак Экспресс

Quick links to important sections

Зодак Экспресс

Selected form

Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Зодак Экспресс

Zodak Express: At a Glance

Property Description
Active Ingredient Levocetirizine dihydrochloride
Form Film-coated tablets (Oral)
Pharmacological Class Selective H1-Histamine Receptor Antagonist
Common Use Symptomatic relief of allergy
Origin Synthetic (chemically produced)

What Type of Medicine is Zodak Express?

Zodak Express is a single-ingredient, synthetic antihistamine medication primarily intended for the symptomatic relief of allergic conditions. It belongs to the Selective Histamine H1 Receptor Antagonist pharmacological class, a designation supported by major regulatory bodies. This compound is manufactured by Zentiva, a pharmaceutical company headquartered in the Czech Republic, and is frequently available over the counter (OTC), indicating its established profile for general public use.

As a third-generation compound, its key differentiating feature is its high affinity and selectivity for H1 receptors. This action is clinically recognized for providing effective anti-allergic relief while minimizing the potential for side effects, such as drowsiness, that are often associated with older antihistamine drugs.


What is its Composition and Principle of Action?

The active ingredient in the product is Levocetirizine dihydrochloride (INN: Levocetirizine), which is supplied as film-coated tablets for oral administration. Levocetirizine is the pure, active L-enantiomer of cetirizine, which accounts for its potent action. The “Express” positioning highlights a formulation designed for a rapid onset of action after swallowing.

The drug's core principle of action is to block the effects of histamine, the natural substance released during an allergic response. By acting as a competitive inhibitor, Levocetirizine prevents histamine from activating the receptors that trigger symptoms like sneezing, itching, and swelling. This targeted mechanism ensures sustained relief for approximately 24 hours, making it an efficient choice for daily allergy management.

Advertisements

What side effects are possible with Зодак Экспресс?

Possible Side Effects and Safety Information

The safety profile of Zodak Express (levocetirizine dihydrochloride) is structured by regulatory agencies based on frequency and impact on body systems, derived from clinical trials and post-marketing surveillance.

Documented Adverse Reactions

The following table summarizes adverse reactions based on regulatory classifications:

Classification Examples of Documented Effects
Common (1/100 to < 1/10) Somnolence, fatigue, dry mouth, headache, nasopharyngitis.
Uncommon (1/1,000 to < 1/100) Asthenia, abdominal pain.
Rare (1/10,000 to < 1/1,000) Hypersensitivity, tachycardia.
Not Known (Post-Marketing) Aggression, suicidal ideation, convulsion, urinary retention, severe itching upon discontinuation.

These effects are formally categorized under System-Organ-Classes including Nervous System Disorders, Psychiatric Disorders, Gastrointestinal Disorders, and Immune System Disorders.

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions explicitly documented in regulatory labels include Anaphylaxis (a severe allergic reaction), Convulsion, and Urinary Retention. Additionally, a risk of Suicidal Ideation has been reported in post-marketing data.

Safety Constraints for Use:

  1. Contraindications: The medication is formally contraindicated in individuals with known hypersensitivity to levocetirizine or related compounds, and in patients with end-stage renal disease (Creatinine Clearance less than 10 mL/min).
  2. Special Populations: Caution is advised for older adults due to the greater likelihood of decreased renal function. The drug is contraindicated in young children (6 months to 11 years) with renal impairment.
  3. Exposure Patterns: A pattern of severe pruritus (itching) has been noted upon discontinuation of the medicine, especially following long-term use, a risk documented in official safety information.
Advertisements

Overdose and Emergency Response

The officially documented profile for a levocetirizine dihydrochloride (Zodak Express) overdose focuses on central nervous system (CNS) effects and mandated emergency actions. Overdose manifestations are differentiated by age group. In adults and adolescents, the primary presentation is typically somnolence or drowsiness. Conversely, pediatric overdose often begins with agitation or restlessness, which may then be followed by symptoms of drowsiness.

A large acute ingestion carries the potential for severe outcomes, including significant CNS depression and cardiovascular effects. Documented serious manifestations noted in regulatory summaries include the possibility of seizures and cardiac arrhythmia.

If an overdose is suspected, immediate medical attention must be sought. Official health authorities mandate that emergency services be contacted if an individual displays life-threatening symptoms, such as trouble breathing, collapse, a seizure, or the inability to be awakened.

Management of levocetirizine overdose is confined to symptomatic and supportive treatment, as regulatory documents explicitly state that no specific antidote is known. Hospital observation and monitoring, including cardiac monitoring, may be necessary to manage severe clinical signs. Procedures such as gastric lavage or the administration of activated charcoal may be considered by healthcare providers shortly after ingestion.

Advertisements

Therapeutic Uses of Зодак Экспресс

What Зодак Экспресс Treats: Main Uses and Benefits

Zodak Express is used to provide symptomatic support across clinical settings involving allergic reactions. The medication is applied in addressing conditions characterized by periods of heightened symptoms, including seasonal allergic rhinitis, perennial allergic rhinitis, and chronic idiopathic urticaria (hives).

The medication helps address symptom clusters that may become intense or disruptive, such as frequent sneezing, runny nose, nasal itching, and itchy, watery eyes. It is also relevant for easing the symptomatic burden of persistent skin itching (pruritus) associated with hives. The primary therapeutic benefit may assist in supporting continuous symptomatic relief, contributing to improved comfort during periods of heightened symptoms.

“This supports general well-being during symptomatic phases, helping patients cope more steadily with symptom fluctuations.”

This supportive action is relevant when symptoms become more noticeable, assisting with maintaining functional stability.


Quick Fact: Relief for Allergy Symptoms
Symptom Axes: Supports management of symptoms related to inflammatory and irritative states.
Relief Focus: Applied in addressing itching (nasal, ocular, skin) and fluid discharge (runny nose, watery eyes).

Advertisements

Eligibility and Restrictions for Use

Official Population Eligibility for Зодак Экспресс

Regulatory documents define strict eligibility based on age, kidney function, and known allergies to the active ingredient, levocetirizine dihydrochloride. The medicine is approved for use in adults and adolescents 12 years of age and older. Children aged 6 to 11 years are also approved for use with a reduced dosage (typically a half-tablet).


Contraindicated Populations Restricted/Conditional Use Not Recommended Group
Severe Renal Impairment (e.g., end-stage kidney disease or hemodialysis) Patients with mild or moderate renal impairment require a restricted, adjusted dosing schedule. The tablet formulation is not recommended in children under 6 years due to the inability to achieve appropriate dose adaptation.
Hypersensitivity to levocetirizine, cetirizine, or any piperazine derivatives Pregnancy and Lactation require caution due to limited clinical data. Use has not been established in infants younger than six months of age.
Pediatric patients 6 to 11 years with any degree of impaired renal function Caution is advised in patients with risk factors for urinary retention or convulsions.

Eligibility is not restricted for patients with solely hepatic impairment.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions for levocetirizine dihydrochloride documented in government regulatory sources.


Interaction scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions: Central Nervous System (CNS) depressants (general class).
Specific interacting medicines (if explicitly listed): Ritonavir (increased exposure) and Theophylline (minor reduction in clearance).
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic (additive CNS depression) and Pharmacokinetic (altered clearance/absorption rate). Minimal involvement in major Cytochrome P450 (CYP) isoenzyme metabolism.
Timing-based interaction rules (if applicable): None mandatory for administration with food; the drug can be taken without regard to meals.
Population-specific interaction notes (if applicable): Risk of adverse reactions may be greater in patients with impaired renal function due to the drug being substantially excreted by the kidneys.
Interaction-related restrictions: Concurrent use with alcohol or other CNS depressants should be avoided due to the potential for additional reductions in alertness.

Interaction classifications (high-level)

Classification Official Regulatory Statement
Interaction severity classification (as defined in official documents): Co-administration with alcohol/CNS depressants is an Avoid Concurrent Use restriction. Ritonavir co-administration results in a significant increase in exposure (AUC).
Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information and Clinical Pharmacology Reviews.
Interaction-context constraints (as defined in official documents): The Food Effect alters the rate of absorption, causing a delayed time to maximum plasma concentration (Tmax) and a reduced peak concentration (Cmax), but the total systemic exposure (AUC) remains unchanged.

Resulting interaction structure

Official interaction statements primarily define the product's profile by the risk of additive pharmacodynamic effects with alcohol and other CNS depressants, necessitating avoidance of concurrent use. The key pharmacokinetic interaction involves ritonavir, which officially increases levocetirizine exposure by approximately 42% due to altered clearance. The drug's minor metabolism minimizes the potential for interactions via common CYP enzyme inhibition. The food interaction is classified as modifying the rate of absorption, which does not require a mandatory administration timing separation.

Advertisements

Mechanism of Action

How Зодак Экспресс Works

The primary action of Levocetirizine is as a selective competitive antagonist of the peripheral Histamine H1 Receptor ( H1 R). By binding to this receptor with high affinity, the molecule blocks the signaling cascade initiated by histamine, the endogenous mediator of H1 R-mediated vascular and smooth muscle effects. The molecule possesses low blood-brain barrier penetration, which directs functional H1 R antagonism primarily toward peripheral systems.

This receptor blockade directly modifies two physiological systems: the microvasculature and smooth muscle tissue. The mechanism reduces histamine-induced dilation and fluid leakage from the vascular endothelium, thereby restricting plasma extravasation into tissues. The drug furthermore limits the histamine-driven contraction of smooth muscles in relevant tissues. These effects initiate rapidly due to the molecule's fast binding kinetics.

Beyond simple receptor antagonism, the drug engages mechanisms that influence the cellular inflammatory pathway. It acts as an inhibitory modulator to reduce the movement and adhesion (chemotaxis) of key immune cells, particularly eosinophils, toward sites of inflammation. This secondary biological action results in the functional reduction of cellular infiltration within targeted inflammatory pathways.

Advertisements

Dosage and Administration Information

How to use Зодак Экспресс

The administration of Зодак Экспресс, which contains levocetirizine dihydrochloride, follows a standardized oral route. The standard maximum daily regimen for adults and adolescents aged 12 years and older is 5 mg administered once daily. The medication may be taken without regard to food (with or without a meal), and administration typically occurs in the evening. The film-coated tablet is scored, allowing for the precise administration of the 2.5 mg half-tablet dose where a lower dose is deemed sufficient.

The fundamental frequency pattern is once daily, and the total daily intake must not exceed 5 mg for adult populations. For children aged 6 to 11 years, the labeled dose is 2.5 mg once daily, which must not be surpassed. For the youngest population, 6 months to 5 years, the labeled dose is 1.25 mg once daily.

A procedural condition involves dose adjustment for patients with reduced kidney function. Depending on the degree of renal impairment, the dose is reduced to 2.5 mg daily, every other day, or twice weekly, reflecting the drug’s clearance pathway. Treatment duration may be intermittent for temporary, acute symptom phases, or continuous for persistent or perennial conditions.

This administration profile is structured around a simple, oral, once-daily pattern. Dose adjustments for renal function and age are utilized to maintain the established parameters for the medication's use.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Зодак Экспресс


Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Clinical studies were used in research exploring how patient-reported symptoms related to allergic rhinitis (seasonal and perennial) change over time. The compound was studied for its potential in trials assessing short-term or episodic symptom patterns, relevant in evidence describing how symptoms are measured. The primary research basis for this condition consists of Randomized Controlled Trials (RCTs). Researchers evaluated these outcomes related to physical discomfort by measuring changes in specific allergy symptom scores, often alongside assessments of health-related quality of life.

The studies were conducted during periods of increased symptom activity and compared the compound against an inactive control (placebo) or sometimes against other active compounds. Studies reported measurements of symptom scores over the observation period, with numerical differences observed between groups receiving the compound and groups receiving placebo. Research describes that the compound was studied for conditions characterized by fluctuating or episodic manifestations.


Evidence for Use in Chronic Idiopathic Urticaria (Hives)

The research for chronic idiopathic urticaria (hives) was evaluated in Randomized Controlled Trials (RCTs) that focused on conditions characterized by periods of heightened symptoms. Studies focused on episodes where symptoms become more noticeable, particularly exploring outcomes related to physical discomfort like the intensity of itching (pruritus) and the physical manifestation of the rash. Outcomes describing episodic or acute changes were monitored using specific tools like the Urticaria Activity Score.

Studies monitored symptom intensity or variability over defined time intervals, typically lasting a few weeks to a few months. Research provides insight into short-term changes, with findings related to how the severity of itching and the number and size of hives evolved in the study groups. Studies report how symptoms evolved in the observed populations when compared to the placebo group. This evidence contributes to understanding symptom patterns in conditions where symptoms may vary in intensity.


What Remains Uncertain and Areas for Future Study

The existing evidence contributes to the broader evidence landscape but also indicates several areas where research is ongoing or where certainty remains low. One acknowledged area is the specific effect on the symptom of nasal congestion. While studies examined overall symptom scores, research provides limited information regarding the specific effect on nasal congestion. Comparative evidence with other therapeutic options is also lacking.

Furthermore, a key limitation is that there is limited information for long-term outcomes across all populations. Follow-up durations were limited in the most high-quality studies. The evidence quality varies across studies, and findings were mixed in a small number of trials, suggesting that subgroup findings are uncertain until further, more focused research explores these discrepancies. Study results reflect the specific conditions under which they were conducted.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Зодак Экспресс (FAQ)


Q: Is Зодак Экспресс the same as regular Зодак?

A: Зодак Экспресс contains the active ingredient levocetirizine dihydrochloride. Regulatory documents describe levocetirizine as the active part of cetirizine. Any difference between Зодак Экспресс and another product would depend on a review of their respective official product labels.


Q: How long does the effect of one dose of Зодак Экспресс last?

A: According to official product information, this medicine is typically administered once daily. Clinical pharmacology data supports this dosing schedule by indicating a duration of action that provides symptom relief for approximately 24 hours.


Q: Is Зодак Экспресс safe to use during pregnancy? (Informational only)

A: Official regulatory documents advise that this medicine should be used during pregnancy only if a potential benefit outweighs any potential risk to the fetus. This caution is based on the limited clinical data available regarding its use during pregnancy.


Q: Are there any safety concerns for taking Зодак Экспресс while breastfeeding? (Informational only)

A: Regulatory documentation states that the medicine's active ingredient, levocetirizine, is excreted in human milk. Therefore, the medication is generally not recommended while breastfeeding, or official caution is advised.


Q: Is it safe to drive or operate machinery after taking Зодак Экспресс?

A: Official regulatory documents explicitly caution patients about engaging in hazardous activities, such as operating heavy machinery or driving a vehicle. This caution is in place because regulatory documents indicate the medicine may cause adverse effects like drowsiness or impaired alertness.


Q: What are the known interactions between Зодак Экспресс and pain relievers?

A: Official interaction warnings primarily focus on Central Nervous System (CNS) depressants, as this may lead to additive drowsiness. Non-prescription pain relievers are generally not specifically listed as major interactors, but all product labels should be reviewed.


Q: Does taking Зодак Экспресс with food affect how well it works?

A: The medicine can be taken with or without food. Official clinical information shows that while taking it with a meal might slightly delay how quickly the drug is absorbed into the bloodstream, the total amount of medication that reaches the body's system remains the same.


Q: Is Зодак Экспресс suitable for treating chronic (long-lasting) hives?

A: Yes, according to official regulatory labels, the medicine is indicated for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria (long-lasting hives of unknown cause) in approved patient populations.


Q: What does the official documentation say about the effects of Зодак Экспресс on the heart?

A: Official documentation notes that some effects on the cardiovascular system have been reported. For instance, tachycardia (a fast heart rate) is listed as a rare or post-marketing adverse reaction.


Q: Is it possible for Зодак Экспресс to stop working after long-term use?

A: Official regulatory information does not contain a statement confirming that the medicine stops working (tolerance). However, official warnings describe a post-marketing risk of severe itching (pruritus) upon discontinuation of the medicine, particularly following long-term use.


Q: What kind of allergies is Зодак Экспресс typically used for?

A: Official regulatory indications state that the drug is used for the relief of symptoms associated with allergic rhinitis (including seasonal allergies like hay fever and perennial allergies) and for treating the skin manifestations of chronic idiopathic urticaria (hives).


Q: Is it possible to take Зодак Экспресс with cold or flu medicines?

A: Official regulatory information advises caution against taking this medicine with any products that may cause drowsiness or suppress the Central Nervous System (CNS). Because many cold and flu medicines contain ingredients that cause drowsiness, it is recommended to review labels carefully.


Q: Are there any foods or drinks that should be avoided when taking Зодак Экспресс?

A: The only substance with a formal restriction in the official product information is alcohol, which should be avoided due to the potential for additive impairment and reduced alertness. Regulatory documents do not list specific foods to avoid.


Q: What are the official warnings about using Зодак Экспресс with certain other medicines?

A: Official warnings focus on the risk of increased side effects when used with alcohol or other CNS depressants (substances that slow brain activity). Additionally, warnings state that co-administration with the medicine ritonavir can significantly increase the exposure of levocetirizine in the body.


Q: Why do some people feel dizzy after taking certain allergy medications?

A: Official regulatory documents list dizziness and somnolence (drowsiness) as documented side effects for this medication. These effects are generally associated with the drug's action as an antihistamine, which can sometimes have minor effects on the Nervous System.


Q: What is the main purpose of the research studies mentioned for this drug?

A: The main purpose of the clinical research was to formally demonstrate that the drug is both effective and safe enough for the approved patient groups and conditions. The studies specifically focused on relieving symptoms of allergic rhinitis and treating chronic idiopathic urticaria.


Q: Is it true that Зодак Экспресс has less sedation risk than older allergy drugs?

A: The drug is described in official documentation as having low blood-brain barrier penetration. This is the pharmacological characteristic that forms the basis for the reduced potential for the sedative effects commonly associated with older-generation antihistamines.


Q: What should I do if I experience a side effect not listed in the official documents?

A: Official health agencies provide mechanisms for reporting unexpected side effects, such as post-marketing surveillance programs, and reactions can be discussed with a healthcare provider.


Q: Can Зодак Экспресс be used for skin itching or hives?

A: Yes, regulatory documents indicate that the drug is officially used for treating the manifestations of chronic idiopathic urticaria (hives) and is used to relieve associated symptoms such as skin itching (pruritus).


Q: Why do official documents mention caution for elderly patients using Зодак Экспресс?

A: Caution is officially advised for older adults primarily because they are more likely to have decreased kidney function. Since the drug is mostly cleared from the body by the kidneys, reduced kidney function may result in increased drug exposure, which can increase the risk of side effects.


Q: Can the medication affect my blood pressure?

A: Official adverse event reporting includes rare post-marketing reports of changes in blood pressure, such as both hypotension (low blood pressure) and hypertension (high blood pressure). These are generally classified as uncommon or rare effects in the safety profile.


Q: What is the general advice about what to do in case of overdose?

A: Official regulatory documents advise that patients should immediately seek emergency medical attention or contact a Poison Control Center if an overdose is suspected. Symptoms of overdose are generally described as involving excessive drowsiness in adults or agitation in children.


Q: Can Зодак Экспресс be used as a preventative measure for allergies?

A: Official regulatory documents indicate that the drug is approved for the relief of symptoms associated with allergic conditions. This typically means it is used when symptoms are actively occurring or expected, rather than as a general, non-symptomatic preventative measure.


Q: What research has been done on the use of Зодак Экспресс in combination with other allergy treatments?

A: Official clinical studies that form the basis for the drug's approval primarily focus on the drug's effect when used alone (monotherapy) compared to a placebo or other active control. The regulatory labels do not typically summarize extensive research on its use in combination therapies.


Q: Is Зодак Экспресс described as an effective treatment in official medical guidelines?

A: Official documents, such as the product label, confirm that the drug is approved for the symptomatic treatment of allergic rhinitis and urticaria. This designation confirms its demonstrated efficacy in clinical trials, meeting the standards for regulatory acceptance.


Q: Are there any known effects of Зодак Экспресс on mental clarity or focus?

A: Regulatory documents list side effects such as somnolence (drowsiness), dizziness, and fatigue. Official warnings also caution that the medicine may impair mental alertness, which may affect focus or clarity.


Q: Does the time of day I take Зодак Экспресс matter for its effect?

A: The drug is officially recommended to be taken once daily in the evening. This timing is generally advised in the regulatory documents to minimize the impact of possible somnolence (drowsiness), which is a common side effect, on daily activities.


Q: Why is the drug's ingredient listed as a 'hydrochloride'?

A: The term 'dihydrochloride' is a chemical designation that indicates the active drug, levocetirizine, is provided in a salt form. This salt form contributes to the drug's stability and solubility, which are chemical properties necessary for proper absorption.

Advertisements

How should Зодак Экспресс be stored and disposed of?

How to Store and Dispose of Zodac Express

Storage and disposal procedures for Zodac Express (Levocetirizine dihydrochloride) are strictly defined by regulatory requirements to ensure product quality and environmental safety.


Official Storage Conditions

The medicine must be stored at a temperature not exceeding 25°C and should be protected from light and moisture. It is required to keep the tablets in their original container and must be stored out of the sight and reach of children.


Disposal Requirements

Do not use Zodac Express after the expiry date labeled on the packaging. Unused or expired medicine must not be disposed of via wastewater or household waste. Disposal must follow local requirements and pharmaceutical waste procedures to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Зодак Экспресс found in:

A-Z Index: